Tariff ruling unlikely to reverse industry shift toward US investment and global pricing

Many pharmaceutical companies had already begun responding to this environment well before the Supreme Court’s ruling. Over the past two years, several major firms announced substantial investments in U.S. manufacturing capacity and expansions of existing production sites. …